If accepted, Vifor Pharma's £23m offer will "claw back" money for the NHS and close the CMA's first-ever disparagement case.

Vifor Pharma to pay £23m to NHS after competition probe into misleading claims - The competition watchdog was investigating ...

After recently taking steps to undo messaging about a rival product in the European Union, CSL Vifor is carrying its amends ...

The CMA has secured an offer of £23m from Vifor Pharma to the NHS, as part of a wider package, to address concerns that ...

On the heels of a late-stage clinical trial failure, Vifor Pharma has moved to bolster its pipeline by acquiring Spain's Sanifit and fellow Swiss biotech Inositec for a combined value of €225 ...

This case marks the first time the CMA has investigated misleading claims under its competition law enforcement powers. The ...

Vifor Pharma and partner Angion Biomedica have suffered another setback with their drug to prevent organ damage, this time in high-risk kidney transplant patients. A phase 3 trial of ANG-3777 ...

The U.K. Competition Appeal Tribunal (CAT) has imposed its own fines on Pfizer and Flynn Pharma for abusing their dominant positions by ...

CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care). At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical ...

Previously, he was CFO at Vifor Pharma where he was instrumental in the separation of Galenica from Vifor Pharma onto the Swiss Exchange in 2017. During his career, he also served as CFO of Evotec ...